Search This Blog

Saturday, June 28, 2014

GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL | 2014 | Press releases | Media | GlaxoSmithKline





GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL | 2014 | Press releases | Media | GlaxoSmithKline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.